ArticleJournal of the Endocrine Society2025
Safety and Efficacy of Pressure-Enabled Thyroid Embolization: A Novel Approach for Symptomatic Thyroid Disease.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bleomycin TACE for symptomatic giant nodular goiter.European radiology · 2026Article
- Complete pathologic necrosis of a thyroid neoplasm following pressure-enabled thyroid artery embolization.JCEM case reports · 2026Article
- Thyroid Artery Embolization for Benign Thyroid Hyperplasia.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: To assess the safety and efficacy of pressure-enabled thyroid embolization (PED-TAE) for thyroid embolization. Objective: This work aimed to evaluate the safety, feasibility, and early efficacy of PED-TAE via the inferior thyroid arteries in patients with symptomatic thyroid disease. Methods: This retrospective cohort study took place at an academic outpatient clinic. Between May 2023 and July 2024, 22 patients underwent PED-TAE using a pressure-enabled drug delivery (PEDD) device. We retrospectively reviewed patient characteristics, procedure details, and adverse events. Patients were treated with PED-TAE predominantly via transradial access with 100 to 300 µm spheres. Ten patients (45%) underwent preplanned unilateral embolization and 12 (55%) bilateral embolization. Main outcome measures included successful embolization of the targeted thyroid lobe via an inferior thyroid artery only, as well as absence of nontarget embolization, target volume reduction, and normalization of thyroid function when appropriate. Results: Etiology included 11 (50%) multinodular goiters, 6 (27%) toxic nodules/goiters, 3 (14%) pre thyroidectomy, 1 (4%) Graves disease, and 1 (4%) solitary nodule. Technical and clinical success was achieved in all patients. Eighteen patients reported mild pain or discomfort, which resolved within 2 weeks. No neurovascular complications were reported. A total of 71% of patients with hyperthyroidism became euthyroid. Six-month follow-up data were available for 18 patients, in whom the mean gland volume decreased from 184.5 ± 141.4 mL pre procedure to 49.9 ± 33.7 mL ( Conclusion: PED-TAE is safe and feasible, with high euthyroid conversion rates and volume reduction. A multi-institutional study is planned to validate the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.